ALIMTA is approved by the FDA in combination with KEYTRUDA® (pembrolizumab) (an immunotherapy) and platinum chemotherapy (carboplatin or cisplatin, two other chemotherapy drugs) as the first treatment for nonsquamous non-small cell lung cancer (NSCLC) that has spread with no abnormal EGFR or ALK genes.
ALIMTA is not appropriate for people who have a different type of NSCLC called squamous cell.
With ALIMTA® + KEYTRUDA® pembrolizumab (pembro) and platinum chemotherapy (carboplatin or cisplatin), your treatment can fight cancer in 2 different ways, using both chemotherapy and immunotherapy.
By combining chemotherapies called ALIMTA and platinum with an immunotherapy called KEYTRUDA, you can treat the disease more effectively than with chemotherapy alone.
